SCHEMBL9965989

SCHEMBL9965989

CN1CCC2(CC1)OC(=O)C=C2c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.59
DRD2 P14416 4/20 0.59
CHRNA7 P36544 1/20 0.43
DGAT1 O75907 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
POLB P06746 1/20 0.38
SCN1A P35498 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11278945 0.85 SIGMAR1 (0.54) SIGMAR1DRD2DGAT1SMN1; SMN2GRIN2D
SCHEMBL9963269 0.84 CYP2D6 (0.45) SIGMAR1DRD2DGAT1SMN1; SMN2GRIN2D
SCHEMBL31120347 0.81 SMN1; SMN2 (0.53) SIGMAR1DGAT1SMN1; SMN2POLBALDH1A1
SCHEMBL11273432 0.73 SIGMAR1 (0.68) SIGMAR1DRD2GRIN2DGRIN3BGRIN1
SCHEMBL11278990 0.72 SIGMAR1 (0.60) SIGMAR1DRD2GRIN2DGRIN3BGRIN1
SCHEMBL11269471 0.72 SIGMAR1 (0.60) SIGMAR1DRD2SMN1; SMN2GRIN2DGRIN3B
SCHEMBL16274418 0.68 SIGMAR1 (0.47) SIGMAR1DRD2
SCHEMBL12568550 0.68 SIGMAR1 (0.67) SIGMAR1DRD2ALDH1A1
SCHEMBL23508660 0.67 SIGMAR1 (0.48) SIGMAR1DRD2CHRNA7SMN1; SMN2
SCHEMBL4973152 0.67 SMN1; SMN2 (0.40) SIGMAR1DRD2SMN1; SMN2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
WO-2011025690-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 SIGMAR1 152/4885DRD2 162/4885CHRNA7 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.